ACOR News and Press, Acorda Therapeutics Inc. From 12/22/22

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for the third quarter of 2022. The revised guidance corrects certain errors ident...

Acorda Therapeutics ( NASDAQ: ACOR ) said Tuesday it received a Nasdaq notice indicating that its shares will be delisted unless the firm timely requests a hearing before the Nasdaq Hearings Panel. Nasdaq's decision is based on ACOR's non-compliance with the fi...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture. Acorda may elect to make interest payments under the Indenture in cash or shares of the Com...

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the Company’s stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders. “We are grateful to our shareholders who supported this proposal at a rati...

Acorda Therapeutics, Inc. (ACOR) Q3 2022 Results Conference Call November 01, 2022 04:30 PM ET Company Participants Tierney Saccavino - Investor Relations Ron Cohen - President and Chief Executive Officer Michael Gesser - Chief Financial Officer Conference ...

Acorda Therapeutics press release ( NASDAQ: ACOR ): Q3 GAAP EPS of -$0.57. Revenue of $33.51M (+6.5% Y/Y). Shares +1.2% . INBRIJA (levodopa inhalation powder) Q3 2022 U.S. net revenue of $7.8 million; 1% increase over Q3 2021 AMPYRA (dalfampr...

INBRIJA ® (levodopa inhalation powder) Q3 2022 U.S. net revenue of $7.8 million; 1% increase over Q3 2021 AMPYRA ® (dalfampridine) Q3 2022 net revenue of $21.1 million; 5% increase over Q3 2021 $16.5M award and royalty/supply relief in AMPYRA arbitration...

Acorda Therapeutics, Inc. ( NASDAQ: ACOR ), a biotech focused on neurological disorders, added over 25% on Thursday after announcing its long business strategy and financial guidance, including plans to become positive cash flow in 2023. Its ability to implement the st...

CEO video / Q&A with shareholders on October 28, 2022 to review business plan and ballot items for special meeting of stockholders Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a detailed, long-term business plan to drive shareholder value and also prov...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://eve...